Introduction
Ovarian cancer is the most fatal gynecologic malignancy in the US, and the incidence is reported to be increasing. 1 Approximately 70% of patients with ovarian cancer will present with advanced stages of the disease. Despite modern treatment modalities consisting of surgery and chemotherapy, the majority of patients will experience relapse and the response to salvage treatments is often brief. In this regard, gene therapy is a potentially effective therapeutic option for ovarian cancer. Adenoviral (Ad) vectors have been used in a large number of gene therapy approaches due to their capacity to accomplish effective in vivo gene delivery. 2 However, the outcome of clinical trials has failed to fulfill the expectations of preclinical data in terms of therapeutic outcome. Finding ways to target cancer cells, which often express low levels of the primary receptor for serotypes 2 and 5, the coxsackie-adenovirus receptor (CAR), has become an important goal for gene therapy research. Various transductional and transcriptional targeting approaches have been employed to improve targeting of Ad vectors. Transductional targeting alters the natural tropism of the Ad vector typically by modifying the knob domain of the Ad fiber, which normally binds to CAR. Transcriptional targeting involves genetically limiting the expression of the introduced gene to specific tissues through the use of tissue-specific promoters (TSPs). Ectopic liver delivery is the major predicate of Advector-induced toxicity. Therefore, it is rational to choose a TSP, which is highly expressed in the tumor but has potentially low activity in the liver. One of the most attractive candidates for targeted therapy of ovarian cancer is Mesothelin (MSLN), a glycosylphosphatidylinositol-linked cell surface glycoprotein which is overexpressed in different tumor types such as ovarian cancer, mesotheliomas and different squamous cell cancers. 3, 4 MSLN is not present on normal tissues except mesothelial cells, and is also not shed into the blood stream in significant amounts. MSLN gene expression has been evaluated in different cell lines and the corresponding promoter has been characterized. 5 Other studies have demonstrated the effectivity of recombinant antimesothelin immunotoxins on organotypic cultures of ovarian and cervical cancer. 6 Tissue microarray and immunohistochemical analysis of MSLN showed highest mRNA and protein expression levels in ovarian cancer tissues,whereas expression in normal tissues including the liver was low. 7 The 
Results
Evaluation of MSLN mRNA expression and MSLN cell surface protein expression on ovarian cancer cell lines Quantitative RT-PCR was performed to examine the level of MSLN mRNA in the human ovarian cancer cell lines Hey, OV-4 and SKOV3, and the teratocarcinoma cell line PA-1 relative to the human fibroblast cell line (HFBC). Figure 1a shows the results of PCR amplification using primer pairs specific for MSLN mRNA. Of note, the mRNA signals for MSLN in all the three ovarian cancer cell lines tested are 33-55% increased compared to HFBC. The teratocarcinoma cell line PA-1 does not show an increased mRNA level for MSLN compared to HFBC.
Flow cytometry was performed to confirm that MSLN is expressed on the cell surface of ovarian cancer cell lines. As expected, MSLN was highly expressed on the surface of all ovarian cancer cell lines tested (76.48-99.7% positive cells). In contrast, MSLN was not detected on the surface of the negative control cell line HFBC (2.96% positive cells) or significantly lower expressed on the surface of the teratocarcinoma cell line PAI-1 (26.65% positive cells) (Figure 1b ). Taken together with the RT-PCR analysis, these findings demonstrate that the native MSLN promoter is active in various ovarian cancer cell lines and the mRNA is translated into MSLN protein localized at the cell surface.
Evaluation of the MSLN promoter activity in ovarian cancer cell lines
After having detected high expression rates of the MSLN gene, we tested the activity of the MSLN promoter in ovarian cancer cell lines. Plasmids carrying the luciferase reporter gene were transfected into cell lines, and luciferase and protein assays were performed 24 h later. The activity of the MSLN promoter was 14.4, 9.7%, 12.3% in SKOV3, Hey and OV-4 cell lines, respectively. In contrast, the MSLN promoter activity in PA-1 cells was only 1.6% of the cytomegalovirus (CMV) promoter activity. The differences of the promoter activity strongly correlated with the expression profile of the MSLN gene ( Figure 1a) . In each case, a promoter-less plasmid was included to determine the background activity of luciferase. With the exception of PA-1 cells, expression achieved with pMSLN.LUC was significantly higher than with the promoter-less plasmid (Po0.05 for SKOV3, Hey and OV-4).
To determine whether the MSLN promoter retains its fidelity in the context of a clinically applicable vector, we constructed an adenovirus, AdMSLN.Luc, where the MSLN promoter was placed upstream of the luciferase marker gene. Promoter activity was compared to that of the ubiquitous CMV promoter (Figure 2b To more closely model the clinical situation with the most stringent substrate, gene transfer experiments were performed using unpassaged human primary ovarian cancer cells. In our experiments, primary cancer cells obtained from three patients were infected with Ad-MSLN.Luc. Promoter activity was compared to that of the ubiquitous CMV promoter (Figure 2c ). At a viral dose of 10 PFU/cell, gene expression controlled by the MSLN promoter resulted in 12.6, 11.6 and 8.7% of the expression achieved with the CMV promoter in the three patient samples.
MSLN promoter in Ad context has low activity in nontarget cells in vivo
A key limitation to the use of a systemic gene therapy approach is the potential toxicity to nontarget organs. Due to the high tropism of Ad-based gene therapy vectors to the liver, we were especially interested in determining whether the MSLN promoter would have a low liver activity in vivo. Thus, AdMSLNLuc and AdCMVLuc (as a positive control) were injected intravenously (i.v.) into mice. At 48 h, liver, spleen, lung, kidney and heart were harvested and luciferase activity and protein concentration of tissue lysate were measured. In this assay, transgene expression induced by the MSLN promoter was 19.5-, 6.8-, 9.8-, 5.4-and 2.7-fold (Po0.05) less expressed than that with the CMV promoter in liver, spleen, kidney, lung and heart, respectively ( Figure 3 ). These results demonstrate that the MSLN promoter in the context of an Ad vector possesses the key element, of a low-level expression in the liver, for consideration for use for cancer gene therapy. 
In vitro transduction of ovarian cancer cells with the MSLN-targeted vector

Discussion
Gene therapy applications in which viral vectors are used for gene transfer have shown great promise in preclinical studies. Unfortunately, inefficient tumor transduction has often precluded significant benefit in clinical trials. One key requirement for endeavoring molecular therapeutics for cancer is a higher therapeutic index than for the currently available modalities. To increase the specificity of Ad-mediated gene therapy, we employed the MSLN promoter and surface protein for transcriptional and transductional targeting, respectively.
We examined a panel of ovarian cancer and teratocarcinoma cell lines to evaluate transcriptional activity of the MSLN gene and MSLN surface protein expression. All close correlations were observed for the ovarian cancer cell lines (Figure 1 ). These findings correlate with previous reports about high MSLN mRNA and protein levels in ovarian cancer cell lines and tissues. 7, 9 When we evaluated MSLN promoter-driven reporter gene expression in the context of Ad vector gene transfer, an average of the MSLN promoter activity in ovarian cancer cell lines and primary ovarian cancer patient samples reached 10% observed for the highly active CMV promoter. Recent studies, evaluating promoter activity and CRAD efficiency in the context of ovarian cancer gene therapy, have demonstrated that even lower promoter activities can be regarded sufficient to achieve therapeutic efficacy. 10 It is important to note that the human fibroblast cell line and the teratocarcinoma cell line PA-1, which we used as a control, showed low MSLN promoter activity. The high MSLN to CMV promoter ratio in nonovarian cancer cell lines indicates the high tissue specificity of the MSLN promoter. Our results demonstrate that the MSLN promoter is transcriptionally active in ovarian cancer. Importantly, the MSLN promoter activity in the liver, where MSLN is not expressed, was very low. The high activity and narrow tissue specificity make it a promising promoter for ovarian cancer gene therapy.
One major factor for inefficient gene transfer in the context of Ad-mediated gene therapy is the low expression rate of the requisite receptor CAR on primary tumors. Previous studies have reported a relationship between low CAR levels and low tumor transduction rates. 11 Therefore, it is a rational approach to direct gene therapy agents to targets more prevalent in specific tumor tissues. The high expression rates of the MSLN surface protein suggest a high potential for transductional targeting strategies for ovarian cancer. Recently, studies have demonstrated the antitumor efficiency of a Mesothelin-mediated targeting M Breidenbach et al recombinant antimesothelin-immunotoxin against gynecologic tumors, 6 including ovarian and cervical cancer, as well as lung cancer. 12 Previous studies 13 had demonstrated the value of a monoclonal antibody that recognizes the MSLN cell surface glycoprotein on ovarian cancer cells for diagnostic and therapeutic purposes. A novel approach was used as a test system to evaluate the value of MSLN for transductional targeting in the context of ovarian cancer gene therapy. This approach consists of an Ad vector that incorporates the Ig-binding domain into the Ad fiber, allowing cellspecific targeting via Fc-containing antibodies. The data generated with the MSLN-targeted Ad vectors were compared to a control group of Ad vectors targeted to ACE, which is not specifically expressed in ovarian cancer. In our study, transductional targeting to MSLN resulted in a significantly increased transduction rate in all ovarian cancer cell lines tested. Of note, transductional targeting to MSLN did not increase gene transfer rates in human fibroblast cells or the teratocarcinoma cell line used in this study. This indicates the high tissue specificity of MSLN and corresponds to results obtained from FACS analysis and transcriptional targeting experiments. The data generated with primary ovarian cancer cells purified from patient ascites confirm the results obtained from established ovarian cancer cell lines. The latter displayed a 1 log increased gene transfer rate when targeted to MSLN, whereas results in purified ovarian cancer cells were more variable. Since the purification of primary ovarian cancer cells requires several steps of treatment with trypsin, we hypothesize that this treatment affects transductional targeting due to partial damage of MSLN surface proteins. In conclusion, we have identified MSLN as a tumor-associated promoter that is activated in ovarian cancer. We have clearly demonstrated its use for transcriptional targeting approaches, whereby the high tissue specificity of the MSLN promoter is of great value in the context of ovarian cancer gene therapy. In addition, we have demonstrated the potential use of MSLN for transductional targeting. A recent study has demonstrated the use of a combined transcriptional and transductional targeting approach in vivo.
14 In this study, an endothelialspecific promoter has been combined with transductional targeting of a systemically administered Ad vector to a pulmonary endothelial marker, resulting in significantly increased improvement of transgene expression in the lung versus the liver. However, until now, transductional and transcriptional targeting is limited by the existence of few truly cancer-cell-specific receptors and promoters, respectively. Unfortunately, many candidate target receptors are also expressed at low amounts in normal tissue. 15 In this regard, targeting adenoviruses to MSLN offers a clear advantage due to its narrow tissue specificity over many other targeting moieties examined so far. Combined targeting approaches in the context of adenovirus-based gene therapy have examined cross strategies, such as combinations of tumor-specific promoters and bispecific antibodies. 16, 17 Our study offers the possibility to expand the concept of a dual targeting approach with combined transcriptional and transductional targeting to the same tumor-specific regulatory element. Such a dual targeting strategy would have a great potential to increase the efficiency and specificity of targeted gene therapy for cancer gene therapy applications in the near future. MSLN is capable of playing an important role in targeting gene therapy vectors to ovarian cancer and in improving the safety and efficacy in the treatment of patients.
Materials and methods
Cell lines and ovarian cancer primary cells
Hey, OV-4 and SKOV3 ovarian adenocarcinoma cell lines were kind gifts from Dr Timothy J Eberlein (Harvard Medical School, Boston, MA, USA), Drs Judy Wolf and Janet Price (both from the University of Texas MD Anderson Cancer Center, Houston, TX, USA). The teratocarcinoma cell line PA-1 was purchased from the American Tissue Type Culture Collection (Manassas, VA, USA) and 293 was obtained from Microbix (Toronto, Canada). A normal human fibroblast cell line HFBC was a kind gift from Dr S Boppana (Children Hospital, UAB, Birmingham, AL, USA). Cell lines were maintained in DMEM (Mediatech, Herndon, VA, USA) containing 10% fetal calf serum, penicillin (100 IU/ml) and streptomycin (100 mg/ml). Cells were grown at 371C in a humidified atmosphere of 5% CO 2 . Fresh malignant ascite fluid samples from five patients with pathologically confirmed ovarian adenocarcinoma were obtained from the University of Alabama at Birmingham (UAB) Hospital. Cancer cells were purified using a method described previously. 18, 19 Briefly, ovarian cancer cells were initially bound with a mouse anti-TAG-72-antibody and subsequently collected with magnetic beads coated with antimouse-IgG.
RNA preparation and quantitative RT-PCR analysis
Total cellular RNA of tumor cells was extracted from 2 Â 10 5 cells using the RNeasy mini prep kit (Qiagen, Santa Clarita, CA, USA) and treated with DNase I (Life Technologies Inc., Rockville, MD, USA) for 30 min. PCR product from MSLN was used for creation of the standard curve. GeneAmp RNA PCR core kit (Applied Biosystems, Foster City, CA, USA) was used for cDNA synthesis and PCR amplification of cDNA products. TaqMan primers and probes were designed by the Primer Express 1.0 software and synthesized by Applied Biosystems (Foster City, CA, USA). Oligonucleotide sequences for amplification of the MSLN gene were forward primer GGA CTT GGC CAC GTT CAT G, reverse primer ACC TCA GCC ACA GTC AAC GG and probe 6FAM-AGC ACC GCA TCC GTC CGC AG-TAMRA. The human house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The sequences to amplify GAPDH gene were forward primer GGT TTA CAT GTT CCA ATA TGA TTC CA, reverse primer ATG GGA TTT CCA TTG ATG ACA AG and probe 6FAM-CGT TCT CGC CTT GAC GGT GCC AT-TAMRA. With optimized concentration of primers and probe, the components of real-time PCR mixture were designed to result in a master mix with a final volume of 9 ml per reaction, containing 1 Â TaqMan s EZ RT-PCT Kit (Applied Biosystems, Foster City, CA, USA), 100 nM forward primer, 100 nM reverse primer, 100 nM probe and 0.025% BSA. In all, 1 ml of total RNA sample was added to 9 ml of PCR mixture in each reaction capillary. A negative control (no template) received 1 ml of water. For 6 , 10 4 and 10 2 copies/ml) was amplified to generate a standard curve for quantification of the CMV copy numbers of unknown samples. All capillaries were then sealed and centrifuged using LC Carousel Centrifuge (Roche Molecular Biochemicals, Indianapolis, IN, USA) to facilitate mixing. All PCR reactions were carried out using a LightCyclert System (Roche Molecular Biochemicals, Indianapolis, IN, USA). Thermal cycling conditions were 2 min at 501C, 30 min at 601C, 5 min at 951C and 40 cycles of 20 s at 941C and 1 min at 601C. Data were analyzed using the LightCycler software.
Analysis of MSLN expression by flow cytometry
Ovarian cancer cell lines and control cell lines were plated in 60-mm dishes at 1 Â 10 6 cells/dish. At day 3, cells were collected using 0.53 mM EDTA in phosphatebuffered saline (PBS). For analysis of MSLN surface expression, cells were incubated with a mouse antihuman MSLN monoclonal antibody (Zymed, San Francisco, CA, USA), a mouse anti-ACE monoclonal antibody 20 was used as an isotype control. The cells were then labeled with an FITC-labeled rabbit anti-mouse Fabspecific antibody (Sigma, St. Louis, MO, USA) for 30 min at 41C. The cells were fixed with 1% paraformaldehyde in PBS and stored protected from light at 41C until analysis. Analysis was performed with a FACS Calibur using Cell Quest FACS analysis software (Becton Dickinson, NJ, USA).
Plasmid transfections
We constructed a plasmid containing the luciferase gene under the control of the MSLN promoter (pMSLNLuc). To isolate the MSLN promoter, genomic DNA was prepared from human peripheral blood lymphocytes using phenol/chloroform/isoamyl alcohol extraction. Oligonucleotide sequences for amplification of the 1850 bp MSLN promoter were forward primer 5 0 -GCT GGT ACC GTT TTC ATC ATT GTC CGC AGC-3 0 and reverse primer 5 0 -ATA TAA GCT TGA GGG AGG GAC CGT GGG TC-3 0 . Thermal cycling conditions were: 5 min at 941C, followed by 30 cycles of 45 s at 941C, 1 min at 631C and 1 min at 721C. The generated MSLN promoter was ligated into the pGL3-basic plasmid (Promega, Madison, WI, USA) using restriction sites KpnI and HindIII. The plasmid, pGL3, contains the CMV promoter and was used as a control. Ovarian cancer cell lines SKOV3, Hey and OV-4, as well as the teratocarcinoma cell line PA-1, were transfected. The normal fibroblast cell line HFBC served as negative control. Cells were seeded in 12-well plates (500 000 cells/well). On day 2, cells were transfected with pMSLN.Luc or pGL3, using SuperFect reagent (Qiagen, Valencia, CA, USA), and allowed to incubate at 371C for 24 h. Cells were then lysed and analyzed for luciferase expression using Luciferase Assay Systems (Promega, Madison, WI, USA) as suggested by manufacturer. Total protein concentration was measured using a D c Protein Assay (BioRad, Hercules, CA, USA) to allow normalization for the amount of cells.
Viruses and viral techniques
The recombinant Ad vectors AdMSLN.Luc. and Ad-CMV.Luc encode firefly luciferase under control of the 1850 bp MSLN promoter or CMV promoter, respectively.
The MSLN promoter and luciferase gene were excised with KpnI and XbaI from pMSLN.Luc and cloned into the corresponding restriction sites of pShuttle (Quantum Biotechnologies, Montreal, Canada) to create pShuttle.-MSLN.Luc. The resulting plasmid was linearized using PmeI and subsequently cotransformed into Escherichia coli BJ5183 with the pAdEasy-1 backbone plasmid. After confirming recombination, the resulting adenoviral genomes were linearized using PacI and transfected into 293 cells to generate AdMSLN.Luc. Construction of Ad5.DR-LL-Cd has been described previously. 21 All recombinant adenoviruses were propagated in 293 cells and purified by double CsCl density centrifugation. Virus titers were determined by plaque assay in 293 cells.
In vitro gene transfer assays
To quantify transgene expression, 3 Â 10 4 cells per well were plated in 24-well plates. After overnight incubation, cells were infected with AdMSLN.Luc or AdCMV.Luc at a multiplicity of infection (MOI) of 50 in DMEM/F12 media containing 2% FBS (infection medium). After 2 h infection, the medium was replaced with the appropriate complete medium and cultured at 371C in 5% CO 2 . Purified ovarian cancer primary cells were plated at 10 000 cells/well in 96-well plates in 100 ml medium on a rocker. On day 2, cells were infected at an MOI of 10 for 2 h in 20 ml of 2% growth medium (GM) on a rocker. Afterwards, cells were washed once with PBS, and 60 ml 10% GM was added per well. After 24 h, cells were lysed with Reporter Lysis Buffer (Promega, Madison, WI, USA) and lysates were analyzed as described above. Experiments were performed in triplicate and mean values of relative light units (RLU) were calculated. The mean values of AdMSLNLuc were indicated as the percentage of AdCMVLuc in each cell line.
Animal experiments
Mice were obtained at 4-6 weeks of age and quarantined at least 1 week before the study. Mice were kept under pathogen-free conditions according to the American Association for Accreditation of Laboratory Animal Care guidelines. Animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of UAB.
In vivo gene transfer
For determination of luciferase gene expression in mouse organs, C57/BL6 mice (Charles River Laboratories; n ¼ 5/group) received 1 Â 10 9 PFU of AdMSLNLuc, or AdCMVLuc i.v. through the lateral tail vein in a volume of 300 ml of Opti-MEM, or Opti-MEM only. After 48 h, mice were killed and livers, kidneys, lungs, spleens and hearts were harvested and representative sections were snap frozen. The frozen organ samples were ground to a fine powder using a mortar and pestle cooled in a dry ice-ethanol bath. Organ powders were lysed using Cell Culture Lysis Buffer (Promega) at room temperature for 20 min. Lysates were frozen once, then centrifugated at 10 000 g for 15 min. Luciferase activity was measured as before. Mean background luciferase activity was subtracted from the data. The luciferase activity was normalized by protein concentration in the tissue lysate. 10 vp of Ad in 10 ml of PBS for 30 min at room temperature. Data were compared to a negative control consisting of Ad5.DR-LLCd alone or Ad5.DR-LL-Cd incubated with 1.5 mg of a anti-ACE (angiotensin-converting enzyme) monoclonal antibody mAb 9B9, 14 which is not specifically expressed in ovarian cancer cells. Then, the mixtures were diluted with 2% infection medium to 2.5 Â 10 7 vp/ml and 200 ml aliquots were added to the cells. In vitro gene transfer was evaluated as described above.
Statistics
Data are presented as mean values7standard deviation. Statistical differences among groups were assessed with a two-tailed Student's t-test. *Po0.05 was considered significant.
